The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis
Open accessAbstract
Rationale: CD47 plays a vital role in the immune escape of tumor cells, but its role in regulating immune-unrelated biological processes such as proliferation and metastasis remains unclear.We seek to explore the immune-independent functions of CD47 in colorectal cancer (CRC).Methods: The expression of CD47 in CRC was determined by immunohistochemistry.The biological effect of CD47 signaling on tumor cell proliferation and metastasis was evaluated in vitro and in vivo.RNA sequencing analysis was performed to identify pivotal signaling pathways modulated by CD47.The interaction between CD47 and ENO1 was verified by co-immunoprecipitation (co-IP).The effect of CD47 on glycolytic metabolites was analyzed by seahorse XF and targeted metabolomics.Results: The expression of CD47 was upregulated and correlated to poor prognosis in CRC patients.Functional assays revealed that CD47 promoted CRC cell growth and metastasis in vitro and in vivo.Our mechanistic investigations demonstrated that CD47 interacted with ENO1 and protected it from ubiquitin-mediated degradation, subsequently promoting glycolytic activity and phosphorylation of ERK in CRC cells.Inhibition of ENO1 diminished CD47-mediated cell growth and migration.Clinically, the combined expression of CD47 and ENO1 provided reliable predictive biomarkers for the prognosis of CRC patients.Conclusions: CD47 is overexpressed in CRC, and its expression is associated with poor prognosis.Through stabilizing ENO1, CD47 enhances the aerobic glycolysis and ERK activity in CRC cells, thereby promoting the progression of CRC.Our studies reveal an unconventional role of CD47, suggesting that targeting the CD47-ENO1 axis may provide a novel therapeutic avenue for CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 1×
“ENO1 is a key glycolytic enzyme that catalyzes the production of phosphoenolpyruvate (PEP) from 2-phosphoglycerate (2-PG), which plays a crucial role in aerobic glycolysis and facilitates the Warburg effect in cancer cells [40-42].”
BackgroundMetabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · cited 2×
“Immune checkpoint-based therapies, including extracellular blockade of cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death 1 (PD1/PD-L1), exhibit tremendous clinical success in the treatment of multiple cancer types such as melanoma, leukemia, prostate cancer, and CRC [4,5].”
BackgroundMajeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563 · cited 1×
“The degradation of proteins mainly depends on the proteasome system [33].”
BackgroundSamanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302 · cited 1×
“High levels of PD-L1 inhibited cell apoptosis [51], increased chemo-resistance [52], and modulated glucose metabolism in sarcomas [53].”
Background
Cited by
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Emerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., Chai, Y., Song, J., Tang, W., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01885-2 · Cited by 258
Itraconazole inhibits tumor growth via CEBPB‐mediated glycolysis in colorectal cancer
Zhang, Y., Li, L., Chu, F., Wu, H., Xiao, X., Ye, J., & Li, K. (2024) · Cancer Science · doi:10.1111/cas.16082 · Cited by 19
“ENO1 was the only glycolytic enzyme regulated by CEBPB in CRC cell lines, whose tumor-promoting effect has been widely validated in CRC. 12,30 By detecting the effect of CEBPB knockdown on ENO1 expression, we found that CEBPB knockdown in HCT116 significantly decreased the expression of ENO1 at…”
BackgroundSelf-citationLu, Q., Yang, D., Li, H., Zhu, Z., Zhang, Z., Chen, Y., Yang, N., Li, J., Wang, Z., Niu, T., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216660 · Cited by 15
Metadata
- Authors
- Hu, T., Liu, H., Liang, Z., Wang, F., Zhou, C., Zheng, X., Zhang, Y., Song, Y., Hu, J., He, X., Xiao, J., King, R. J., Wu, X., & Lan, P.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 10
- Issue
- 9
- Pages
- 4056-4072
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3012610662
- Cited by
- 160
- References
- 8
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.